

# Head and Neck Disease-Oriented Team

---

## Clinical Research Treatment Trial Flowchart

**Clinical Research Manager:**  
Mehir Tharani

**Clinical Research Coordinators:**  
Bao-An Huynh  
Natalie Arechiga  
Erin Palmer-Torrison  
Anastasiia Reipolska



## Neo-adjuvant or Adjuvant HNSCC

### UCI 22-132

De-escalated Radiation for HPV 16+  
Squamous Cell Carcinoma of the  
Oropharynx  
Coord: E. Palmer-Torrison  
Accrual: 17/111

### HN009

Cisplatin Q3 weeks vs Weekly  
Locally Advanced HNSCC  
Coord: A. Reipolska  
Accrual: 1/5

### UCI 21-173

Eval of Clinical & Radiological Benefit AHCC  
in Combo w/ SOC Tx for HPV+ Pts w/ HNSCC  
Coord: A. Reipolska  
Accrual: 3/34

### UCI 23-190

Observation vs IP  
Adjuvant  
Coord: E. Palmer-Torrison  
Accrual: 0/5

### EA3132 (TP53)

XRT +/- Cisplatin  
Adjuvant  
Coord: A. Reipolska  
Accrual: 0/5

### EA3190

Pembrolizumab  
Adjuvant Recurrent/2ndary HNSCC  
Coord: N. Arechiga  
Accrual: 0/5



### 1<sup>st</sup> Line Recurrent/Metastatic HNSCC

#### UCI 23-106

Pembro + Danvatirsen vs Pembro in  
1<sup>st</sup> line Recurrent/Metastatic HNSCC  
Coord: Anastasiia R.  
Accrual: 2/5

#### UCI 24-130

HPV injection + Pembro  
1<sup>st</sup> line Recurrent/Metastatic  
Coord: TBD  
Accrual: TBD

#### RTOG 3521

Gem+Cis+ Tori  
1<sup>st</sup> line Recurrent/Metastatic NPC  
Coord: N. Arechiga  
Accrual: 1/5

### Recurrent/Metastatic

#### ETCTN 10553

Darolutamide + Leuprolide Acetate in  
Hormone Naïve AR+ Salivary Gland Cancer  
Coord: B. Huynh  
Accrual: 1/5

#### UCI 25-49

Petosemtamab vs Phys Choice  
Recurrent HNSCC  
CRC: TBD  
Accrual: TBD

#### EA3202

2<sup>nd</sup>/3<sup>rd</sup> line Chemo +Cetuximab vs  
Chemo+Bev vs Atezo+Bev  
Recurrent HNSCC  
Coord: E. Torrison-Palmer  
Accrual: 2/5

#### EA3231

BRAF Agent vs Cabozantinib  
Recurrent Thyroid Cancer  
Coord: E. Palmer-Torrison  
Accrual: 0/5

#### Alliance A092105

2<sup>nd</sup> line Ipi/Nivo +/- Cabozantinib  
Recurrent NPC  
Coord: B. Huynh  
Accrual: 0/5



## Broad Phase 1 Trials

### UCI 22-87 (RMC-6236)

Mechanism: TKI  
Coordinator: Oliver  
Quines  
Accrual: 21/25

### UCI 21-40

*(Locally Advanced or Metastatic  
Solid Tumors)*

DF6002 as a Monotherapy  
and in Combination w/ nivo  
Valerin  
CRC: B. Huynh  
Accrual: 5/10  
Waitlist only

### UCI 23-85

BA3182 (CAB T-cell: EpCAM)  
All solid tumors (central EPCAM  
testing)  
Coord: H. Nguyen  
Accrual: 2/5

### UCI 23-148

CJRB-01 (oral) +  
Pembrolizumab  
Mechanism: Live  
biotherapeutic product  
containing a novel strain  
belonging in the species  
*Leuconostoc*  
*mesenteroides* (*L.*  
*mesenteroides* +  
Pembrolizumab  
Coord: J. Choe  
Accrual: 3/6  
accrual hold~ July 2025

### UCI 23-197

DF6215 (IL-2)  
PI: Valerin  
CRC: N. Arechiga  
Accrual: 4/5  
Waitlist only

### UCI 22-09

B7-H4-targeted antibody-drug  
conjugate  
PI: Parajuli  
CRC: N. Arechiga  
Accrual: 5/10  
Waitlist only